Stocks Health care CCCC
NASDAQ · Health careC4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. brought in $32.3M of revenue over the twelve months to September 30, 2026, up 7.2% from a year earlier. It posted a net loss of $91.1M. In fiscal 2025 capital spending exceeded operating cash flow by $99.3M. At September 30, 2026 it held $32.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about C4 Therapeutics, Inc.
- Net worth
- C4 Therapeutics, Inc. has a market value (market cap) of $385.7M at the latest share price, and shareholders' equity of $228.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $35.9M (+1.0% year on year), with a net loss of $105M. Over the 12 months to September 30, 2026: revenue $32.3M, net loss $91.1M.
- Cash flow
- In fiscal 2025 operations used $98.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- C4 Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What C4 Therapeutics, Inc. does
C4 Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CCCC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $35.9M | -$105M | -$1.27 | -$99.3M |
| 2024 | $35.6M | -$105.3M | -$1.52 | -$65.3M |
| 2023 | $20.8M | -$132.5M | -$2.67 | -$108.5M |
| 2022 | $31.1M | -$128.2M | -$2.62 | -$111.4M |
| 2021 | $45.8M | -$83.9M | -$1.82 | -$88.2M |
| 2020 | n/a | -$66.3M | -$5.83 | -$67.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CCCC ranks in Health care
Latest SEC filings
What C4 Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 25% to $8.5M versus the same quarter last year; diluted EPS -$0.16 versus -$0.44.
- November 5, 2026
- September 25, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 2.8% to $6.6M versus the same quarter last year; diluted EPS -$0.18 versus -$0.37.
- August 11, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running C4 Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 4 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Grogan Donna RoyDirector | Received as pay | 4,618 | $14.5K |
| October 1, 2026 | Anderson Kenneth CarlDirector | Received as pay | 3,662 | $11.5K |
| September 18, 2026 | Adams KendraChief Financial Officer | Exercised options | 6,250 | - |
| September 18, 2026 | Adams KendraChief Financial Officer | Shares withheld for tax | 2,775 | $9.4K |
| July 10, 2026 | Reyno LeonardChief Medical Officer | Exercised options | 15,325 | - |
| July 10, 2026 | Reyno LeonardChief Medical Officer | Shares withheld for tax | 7,397 | $30K |
| July 1, 2026 | Anderson Kenneth CarlDirector | Received as pay | 2,650 | $11.5K |
| July 1, 2026 | Grogan Donna RoyDirector | Received as pay | 3,341 | $14.5K |
Who owns CCCC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lynx1 Capital Management LP13G, passive with 1 related filers | 9.99% | August 14, 2026 |
| Soleus Capital Master Fund, L.P.13G, passive with 8 related filers | 9.99% | February 12, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | August 14, 2026 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 9.9% | May 15, 2026 |
| Squadron Master Fund LP13G, passive with 3 related filers | 6.9% | August 14, 2026 |
| BCLS II Equity Opportunities, LP13G, passive with 2 related filers | 6.25% | October 24, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 148 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Morgan Stanley | 8,867,338 | -205,062 |
| RA Capital Management, L.P. | 8,000,000 | 0 |
| BlackRock, Inc. | 7,896,718 | +5,848,192 |
| Lynx1 Capital Management LP | 7,326,691 | +327,789 |
| Squadron Capital Management LLC | 7,200,000 | +4,950,000 |
| Bain Capital Life Sciences Investors, LLC | 7,171,910 | 0 |
| Jpmorgan Chase & Co | 4,747,424 | +1,524,370 |
| Vanguard Capital Management LLC | 4,417,731 | +555,879 |
| Citadel Advisors LLC | 4,187,580 | +1,676,565 |
| Goldman Sachs Group Inc | 3,530,991 | +1,143,613 |
| Wasatch Advisors LP | 3,522,644 | +560,883 |
| Two Sigma Investments, LP | 3,469,707 | +434,073 |
| Soleus Capital Management, L.P. | 3,377,981 | -425,961 |
| Silverarc Capital Management, LLC | 3,032,060 | +1,120,275 |
| Bank of America Corp | 2,656,359 | +297,118 |
| Geode Capital Management, LLC | 2,522,163 | +1,571,120 |
| Ikarian Capital, LLC | 2,433,000 | new |
| State Street Corp | 2,115,621 | +1,732,648 |
| Candriam S.C.A. | 1,796,937 | new |
| D. E. Shaw & Co., Inc. | 1,740,989 | +680,658 |
Insiders
9 insiders reported holding 2,992,254 shares in total, about $9.4M at the last price.
| Holder | Shares |
|---|---|
| Hirsch AndrewPresident & CEO, Director | 1,074,934 |
| Adams KendraChief Financial Officer | 382,323 |
| Reyno LeonardChief Medical Officer | 372,406 |
| Mahaney PaigeChief Scientific Officer | 336,910 |
| Schick KellyChief People Officer | 299,881 |
| Boyle Scott NChief Business Officer | 298,801 |
| Grogan Donna RoyDirector | 79,471 |
| Anderson Kenneth CarlDirector | 75,612 |
| Mossler MarkChief Accounting Officer | 71,916 |
Questions about CCCC
What does C4 Therapeutics, Inc. do?
C4 Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as CCCC. Its shares trade on NASDAQ under the ticker CCCC.
What is C4 Therapeutics, Inc.'s net worth?
C4 Therapeutics, Inc. has a market value (market cap) of $385.7M at the latest share price, and shareholders' equity of $228.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is C4 Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $91.1M on revenue of $32.3M.
How much revenue does C4 Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 C4 Therapeutics, Inc. reported revenue of $32.3M. That is 7.2% more than a year earlier.
When did C4 Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is C4 Therapeutics, Inc.'s next earnings report?
C4 Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CCCC with
Follow CCCC
Get an email when C4 Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values C4 Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.